Regulation of mitochondrial morphology and cristae architecture by the TLR4 pathway in human skeletal muscle.
Lipopolysaccharide
TAK242
mitochondrial dynamics
mitochondrial nanotunnels
skeletal muscle function
type 2 diabetes
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2023
accepted:
12
06
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
In skeletal muscle (SkM), a reduced mitochondrial elongate phenotype is associated with several metabolic disorders like type 2 diabetes mellitus (T2DM). However, the mechanisms contributing to this reduction in mitochondrial elongate phenotype in SkM have not been fully elucidated. It has recently been shown in a SkM cell line that toll-like receptor 4 (TLR4) contributes to the regulation of mitochondrial morphology. However, this has not been investigated in human SkM. Here we found that in human SkM biopsies, TLR4 protein correlated negatively with Opa1 (pro-mitochondrial fusion protein). Moreover, the incubation of human myotubes with LPS reduced mitochondrial size and elongation and induced abnormal mitochondrial cristae, which was prevented with the co-incubation of LPS with TAK
Identifiants
pubmed: 37435031
doi: 10.3389/fcell.2023.1212779
pii: 1212779
pmc: PMC10332154
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1212779Informations de copyright
Copyright © 2023 Castro-Sepulveda, Tuñón-Suárez, Rosales-Soto, Vargas-Foitzick, Deldicque and Zbinden-Foncea.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes. 2008 Oct;57(10):2595-602
pubmed: 18633101
Biosci Rep. 2017 Sep 27;37(5):
pubmed: 28831023
Diabetes Care. 2010 Apr;33(4):861-8
pubmed: 20067962
Sci Rep. 2016 Aug 10;6:30610
pubmed: 27506553
J Mol Endocrinol. 2020 Aug 1;:
pubmed: 32755998
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2207471120
pubmed: 36927155
Am J Physiol Endocrinol Metab. 2010 May;298(5):E988-98
pubmed: 20179247
Cell Prolif. 2023 Feb;56(2):e13362
pubmed: 36433732
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):3048-3061
pubmed: 35978267
Oxid Med Cell Longev. 2018 Jun 26;2018:3181278
pubmed: 30046376
Diabetes. 2014 Jan;63(1):75-88
pubmed: 24009260
Clin Sci (Lond). 2022 Dec 22;136(24):1851-1871
pubmed: 36545931
J Cell Biol. 2016 Feb 29;212(5):531-44
pubmed: 26903540
FASEB J. 2021 Oct;35(10):e21891
pubmed: 34569666
Br J Pharmacol. 2009 Aug;157(7):1250-62
pubmed: 19563534
Metabolism. 2018 Feb;79:42-51
pubmed: 29126696
Diabetes. 2002 Apr;51(4):921-7
pubmed: 11916908
Metabolism. 2023 Jul;144:155578
pubmed: 37164310
Diabetes. 2002 Oct;51(10):2944-50
pubmed: 12351431
Nat Rev Endocrinol. 2012 Apr 03;8(8):457-65
pubmed: 22473333
PLoS One. 2013 May 21;8(5):e63983
pubmed: 23704966
Sci Rep. 2020 Jan 20;10(1):694
pubmed: 31959927
Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E848-E855
pubmed: 32369416
Mol Cell Biol. 2012 Jan;32(2):309-19
pubmed: 22083962
Am J Physiol. 1988 Dec;255(6 Pt 1):E769-74
pubmed: 3059816
Physiol Rep. 2022 Jul;10(14):e15369
pubmed: 35883244
Trends Cell Biol. 2017 Nov;27(11):787-799
pubmed: 28935166
PLoS One. 2017 Jul 24;12(7):e0182040
pubmed: 28742154
Biochem Biophys Res Commun. 2004 Oct 15;323(2):685-95
pubmed: 15369805
Front Bioeng Biotechnol. 2020 Nov 05;8:565679
pubmed: 33224929
Front Physiol. 2021 Mar 01;12:633058
pubmed: 33732165
Physiol Rep. 2021 Apr;9(7):e14808
pubmed: 33904649
FASEB J. 2021 Apr;35(4):e21553
pubmed: 33749943